Agronomics, Oilex and ImmuPharma
Justin Waite
Vox Markets Podcast with Justin Waite
11:45, 11th September 2019

AudioBoom Player

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here:

On today's Vox Markets Podcast: Agronomics, Oilex & ImmuPharma

Richard Reed CBE, businessman, investor, entrepreneur, co-founder of Innocent Drinks and now Chairman of Agronomics (ANIC) FOLLOW talks about why he got involved in the modern food tech sector.

Agronomics Limited (LSE: ANIC) is an investment company that is focused on opportunities within the nascent industry of modern foods, which are environmentally friendly alternatives to the traditional production of meat and plant-based sources of nutrition

Joe Salomon, Managing Director of Oilex (OEX) FOLLOW discusses the agreement they've reached with the Gujarat State Petroleum Corporation which, upon completion, will resolve the ongoing dispute.

Oilex’s strategy is to use its extensive technical and commercial expertise to explore, appraise and develop petroleum resources around the Indian Ocean Rim to meet growing energy demands in the region.

(Interview starts at 21 minutes 9 seconds)

Dr Navid Malik Executive Director at The Life Sciences Division provides on outlook on ImmuPharma (IMM) FOLLOW and its flagship drug Lupuzor, a treatment for autoimmune disease Lupus.

ImmuPharma (AIM: IMM) is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma is led by a commercially focused Board and management team with extensive experience.

(Interview starts at 29 minutes 56 seconds)

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles